Preparation method and application of genetically encoded recombinant collagen-like supramolecular hydrogel

The construction of paired cysteine ​​collagen through gene editing is achieved, and spontaneous cross-linking is solved, which solves the stability and biocompatibility of hydrogels in the field of biomedical science, reduces costs and expands its application potential.

CN116407682BActive Publication Date: 2024-11-22INNER MONGOLIA HEXUN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211398115.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-09
Publication Date
2024-11-22
Estimated Expiration
2042-11-09

AI Technical Summary

Technical Problem

The application of existing hydrogels in the field of biomedical engineering is limited by the problems of poor stability, biocompatibility and high cost, especially the biological side effects and high production costs caused by the need to add crosslinking agents.

Method used

Through gene editing, collagen-like proteins with paired cysteine ​​are constructed, and spontaneous crosslinking is achieved by using cysteine's thiol interaction to achieve spontaneous crosslinking, and a covalent crosslinking protein-based supramolecular hydrocoagulation is prepared without the addition of crosslinking agents. to improve its stability and biocompatibility.

Benefits of technology

A natural hydrogel system without crosslinking agent addition is realized, with stronger biocompatibility and stability, reducing production costs and expanding its application potential in biomedical and tissue engineering.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116407682B_ABST
    Figure CN116407682B_ABST
Patent Text Reader

Abstract

The present invention discloses a preparation method and application of a genetically encoded recombinant collagen-like supramolecular hydrogel, and specifically relates to the field of biomaterials. The preparation method comprises designing a spontaneously cross-linked collagen-like basic sequence, expressing and purifying the target collagen-like protein, and preparing a spontaneously cross-linked protein-based supramolecular hydrogel using the purified collagen-like protein. The present invention prepares a collagen-like supramolecular hydrogel using a biosynthesized paired cysteine-introduced collagen-like protein. The hydrogel achieves covalent cross-linking between protein molecules without adding any cross-linking agent. The hydrogel of the present invention can be used as a raw material for biomedical products such as tissue repair, cardiovascular stents, nerve damage repair, and drug delivery, and has huge market value potential; the research and development technology is at the world's leading level and can contribute to the subsequent development of biomedical materials.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomaterials, and in particular to a gene-encoded recombinant collagen-like supramolecular hydrogel and a preparation method and application thereof. Background Art

[0002] Hydrogels are widely used in the fields of tissue engineering and drug delivery. Producing biomimetic extracellular matrix proteins through biosynthesis and using protein engineering technology to construct protein-based supramolecules as hydrogel skeletons are important directions for the development of medical-grade hydrogels. By introducing cysteine ​​into the extracellular matrix protein series through protein engineering technology, spontaneous cross-linking protein-based hydrogels can be prepared by utilizing the interaction of cysteine ​​thiol groups.

[0003] According to different properties, hydrogel systems can be divided into several different categories. Each hydrogel has its own advantages, but also has its own shortcomings. The preparation of medical-grade hydrogels with strong stability, high biocompatibility and low cost is the key to the current research on hydrogel systems. First of all, due to the non-covalent interactions such as electrostatic effects and intermolecular forces in physical gels, the stability of physical gels is relatively poor. Secondly, chemical gels need to add crosslinkers during the preparation process to catalyze the mutual binding of molecules to form a hydrogel system with relatively stable properties. Although this greatly improves the stability and mechanical properties of hydrogels, the cost of crosslinkers is relatively high and has certain biological side effects, which limits the application of hydrogels in the field of biomedical engineering. Finally, synthetic polymer hydrogels are developed based on chemically synthesized polymer materials. Compared with natural polymer hydrogels, they have poor biocompatibility and high production costs, and crosslinkers also need to be added during the preparation process, which greatly limits the application of synthetic polymer hydrogels. However, although natural polymer hydrogels have high biocompatibility, their mechanical properties and stability are still poor even under the action of crosslinkers due to their natural sequences or chemical structures. Therefore, how to prepare a natural hydrogel system with strong stability, high biocompatibility, low cost and no added cross-linking agent is a major technical bottleneck in current hydrogel research.

[0004] Through gene editing, we construct biosynthetic macromolecular proteins with paired cysteines, and use cysteine ​​to trigger spontaneous cross-linking of extracellular matrix-like proteins to form protein-based supramolecular hydrogels. This can not only improve the problems of mechanical properties and stability of natural proteins, but also achieve covalent cross-linking by utilizing thiol-thiol reactions without adding cross-linking agents, thus breaking through the technical bottleneck of hydrogel research to a certain extent.

[0005] Since physical gels are combined with non-covalent interactions such as electrostatic effects and intermolecular forces, the stability of physical gels is relatively poor. However, chemical gels need to add crosslinkers during the preparation process to catalyze the mutual combination of molecules to form a hydrogel system with relatively stable properties. Although this greatly improves the stability and mechanical properties of hydrogels, the cost of crosslinkers is relatively high and has certain biological side effects, which limits the application of hydrogels in the field of biomedical engineering. Secondly, synthetic polymer hydrogels are developed based on chemically synthesized polymer materials. Compared with natural polymer hydrogels, they have poor biocompatibility and high production costs, and crosslinkers also need to be added during the preparation process, which greatly limits the application of synthetic polymer hydrogels. However, although natural polymer hydrogels have high biocompatibility, their mechanical properties and stability are still poor even under the action of crosslinkers due to their natural sequence or chemical structure.

[0006] The key to the current research on hydrogel systems is to prepare medical-grade hydrogels with strong stability, high biocompatibility and low cost. Therefore, how to prepare natural hydrogel systems with strong stability, high biocompatibility, low cost and no cross-linking agent added is a technical bottleneck in the current hydrogel research. Summary of the invention

[0007] To this end, the present invention provides a preparation method and application of a gene-edited bionic extracellular matrix recombinant collagen-like supramolecular hydrogel. By means of protein engineering technology, paired cysteines are introduced into the artificially designed collagen-like sequence, and the cysteine ​​thiol interaction can be utilized to prepare a spontaneously cross-linked protein-based supramolecular hydrogel.

[0008] The emergence of gene-edited protein-based biomaterials provides new scientific ideas and solutions for the preparation of advanced natural hydrogel systems. Through protein engineering technology, protein-based biomaterials with biological functions are constructed. According to their different functions, they mainly include three parts: a. Skeleton structure: mainly provides basic structure and physical and chemical properties; b. Functional groups: according to their application and functional requirements, introduce biologically active sequences with special functions; c. Reactive groups: groups with reactive properties that can respond accordingly according to different environments.

[0009] By using protein engineering technology to transform extracellular matrix proteins, the extracellular matrix proteins are qualitatively improved in terms of function and physicochemical properties, making them suitable biomaterial skeleton proteins. Natural proteins of the extracellular matrix have certain limitations when used as biomaterials. For example, in eukaryotic organisms, collagen needs to be hydroxylated to form. By using protein engineering technology to construct recombinant collagen, the post-translational modification process of hydroxylation modification can be avoided, and collagen-like proteins can be directly formed, thus breaking through the limitations of traditional collagen post-translational modification. Although extracellular matrix-like proteins exist in various forms in organisms, they cannot bind to biological functional groups, and their diversity is also limited by the types of amino acids in the natural synthesis of proteins. Through recombinant protein engineering technology, corresponding functional groups can be introduced to functionalize extracellular matrix-like proteins, which can effectively enrich the diversity and functionality of extracellular matrix-like proteins.

[0010] Protein-based biomaterials can make up for the shortcomings of traditional chemical polymer materials. Traditional polymer compounds have many limitations as biomaterials: a. Traditional polymer compounds are not homogeneous after metabolism in the body, and drug metabolism detection cannot be achieved, resulting in low drugability. b. The synthesis conditions of polymer compounds are relatively harsh, and the synthesis of polymer compounds often requires a temperature higher than its glass transition temperature, resulting in relatively high temperature requirements. c. Polymer compounds produce toxic gases when decomposed and burned. These conditions limit the application of polymer compounds in the field of biomedicine. d. Polymer compounds have poor biocompatibility. After polymer compounds are metabolized in the body, a variety of heterogeneous compounds are produced. These substances can cause certain immune responses. Protein-based biomaterials make up for the shortcomings of traditional polymer compounds. First, protein-like biomaterials are synthesized by organisms and have mild preparation conditions. Protein-like biomaterials are expressed and produced by gene-edited Escherichia coli. The production process is mild and the purification process does not produce harmful products; secondly, protein-like biomaterials are metabolized into specific amino acids in the body, which are the basic components of organisms and have good biocompatibility. Finally, protein-like biomaterials are homogeneous and metabolized into amino acids in vivo, allowing the detection of their drug metabolism process.

[0011] In summary, the emergence and development of protein-based biomaterials have provided scientific ideas and solutions for the preparation of natural hydrogel systems with strong stability, high biocompatibility, low cost, and no cross-linking agent added.

[0012] In the present invention, first, the construction of collagen-like molecules is one of the core contents of the present invention. This type of collagen is independently designed by the present invention and completes biosynthesis and purification. It is different from traditional biological extraction collagen. Traditional collagen needs to be post-translationally modified by the carrier to stabilize its triple helical structure, and there are no other active groups. The collagen-like protein designed independently by the present invention does not need to be modified by additional post-translation. Through the V-domain at the N end of its gene coding sequence, it stabilizes its triple helical structure by combining the collagen-like protein sequence. Secondly, its collagen sequence is derived from the scl-2 gene of Streptococcus pyogenes. In order to further stabilize its triple helical structure, the collagen sequence is designed as three repetitive scl-2 genes, thereby providing appropriate sequence length and stability. Finally, CPPC polypeptide is added between the V-domain and the collagen sequence and at the C end. The polypeptide is a sequence designed by the present invention to further stabilize the protein structure. The addition of this sequence further ensures the stability of the triple helical structure without the need for additional carrier post-translational modification process.

[0013] The present invention is to construct a spontaneously cross-linked collagen-like supramolecular hydrogel, using the active thiol (-SH) in cysteine ​​to spontaneously react with the cysteine ​​thiol in other collagen-like molecules to form a disulfide bond (-SS-), and a stable cross-network structure is prepared through the disulfide bond as the basic structure of the collagen-like supramolecular hydrogel. Therefore, to achieve the above purpose, CGG and GGC polypeptide sequences are added to the two ends (N-terminus and C-terminus) of the collagen-like sequence, respectively, wherein G is glycine, which exists as a connecting function; C is cysteine, which can provide an active thiol, and the cysteines at both ends can realize the interaction between collagen molecules.

[0014] In order to further enhance the collagen-like function designed by the present invention, the peptide RGD is introduced at the C-terminus of the overall sequence, which can further promote cell attachment, help maintain cell activity and promote cell growth under the support of the protein, thereby expanding its application capabilities in the biomedical, tissue engineering and medical beauty industries.

[0015] In summary, the paired cysteine ​​collagen sequence designed by the present invention is M(CGG)n NADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDGGPCPPCRYPISRPRKRGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAG PKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGGPCPPCRGD(GGC)n C .

[0016] The main method is to introduce V-domin at the N-terminus of the scl-2 gene from Streptococcus pyogenes and connect it with the CPPC polypeptide. The triple scl-2 gene is inserted in the middle, and then two polypeptides, CPPC and RGD, are inserted. It is important to introduce multiple paired cysteine ​​polypeptides, CGG and GGC, at the N-terminus and C-terminus of the overall sequence, respectively, and the number of cysteine ​​polypeptides at both ends is equal, that is, n N =n C (n is any positive integer).

[0017] Another key of the present invention is to use paired cysteine ​​in collagen-like molecules to prepare covalently cross-linked, additive-free collagen-like supramolecular hydrogels. After obtaining paired cysteine ​​collagen-like sequences, collagen-like proteins are prepared by biosynthesis, and then the proteins are used to prepare spontaneously cross-linked collagen-like supramolecular hydrogels. The collagen-like hydrogel prepared by the above method is a protein-based supramolecular hydrogel that is covalently cross-linked by disulfide bonds, and does not require the addition of any cross-linking agent, thereby having stronger biocompatibility.

[0018] In order to achieve the above object, the present invention provides the following technical solutions:

[0019] (1) Biosynthesis and purification of collagen-like proteins

[0020] After obtaining the paired cysteine ​​collagen sequence, it was constructed into the Escherichia coli expression vector pET-28a by molecular cloning technology. Biosynthesize collagen by biofermentation technology. First, the constructed pET-28a-eCLP gene was transferred into BL21 (DE3) expression type Escherichia coli by heat shock transformation or electroporation transformation, and cultured at 37°C. When the OD600 value of Escherichia coli reached 0.6-0.8, IPTG was added to induce Escherichia coli expression. At the same time, the culture system was placed in an environmental condition of 16°C and cultured overnight at a speed of 180rpm / min. After 24 hours, the Escherichia coli was collected by centrifugation.

[0021] The collected E. coli is crushed under high pressure, and the supernatant solution is collected by centrifugation. The protein solution in the supernatant is passed through a nickel column matrix purification column, so that the collagen-like protein with a His tag will bind to the nickel column matrix. The purified collagen-like protein is obtained by eluting with an eluent 3-5 times.

[0022] (2) Reduction of collagen-like proteins

[0023] The present invention introduces paired cysteine ​​polypeptides into collagen-like molecules. In the presence of paired cysteine, this type of paired cysteine ​​polypeptide is prone to form protein aggregates rather than orderly covalent bonding. Therefore, the purified paired cysteine ​​collagen-like molecules need to be reduced. Therefore, the present invention uses a common protein reduction reaction to reduce the above-obtained collagen-like molecules.

[0024] 40mM dithiothreitol (DTT) was added to the obtained collagen-like molecules, and the collagen-like molecules were incubated with shaking for one hour to reduce the disulfide bonds between the collagen-like molecules to sulfhydryl groups, thereby obtaining monomeric collagen-like molecules. In order to further remove the DTT present in the system, a protein concentration ultrafiltration tube was used for purification. The above system was added to a 30kD protein ultrafiltration tube, and an acetic acid / sodium acetate buffer solution with a pH of 6 was added for ultrafiltration washing. After washing 10 times, the reduced collagen-like protein in the acetic acid / sodium acetate solution was obtained.

[0025] (3) Preparation of protein-based supramolecular hydrogels

[0026] The present invention prepares additive-free hydrogel based on the interaction of thiol groups in paired cysteines, so inducing the activation of thiol groups into disulfide bonds is the second key technology of the present invention. Paired cysteines in collagen-like proteins can undergo thiol-disulfide bond exchange reactions under certain conditions, thereby forming covalent bonds between various extracellular matrix protein molecules, thereby spontaneously cross-linking to form hydrogels.

[0027] Using the reaction principle of thiol-disulfide exchange reaction activated in a weak acid environment, the paired cysteine ​​collagen dissolved in PBS is added dropwise to the pre-prepared weak acid (PH=4-5) acetate buffer at a content of 10% (w / v) and reacted for 48 hours. After the reaction, the solution is placed in a pre-made PDMS mold and placed at 4°C for 48 hours. After inducing spontaneous cross-linking of the collagen-like protein, the system is placed in a freeze dryer and freeze-dried for 48 hours. After collecting the lyophilized body, the lyophilized powder is re-dissolved with ultrapure water at a concentration of 10% (w / v), and shaken until the lyophilized body is completely dissolved to obtain the hydrogel.

[0028] According to the second aspect of the present invention, a biomimetic extracellular matrix recombinant protein supramolecular hydrogel is provided, and the gel is prepared by the method described above.

[0029] According to the third aspect of the present invention, a biomimetic extracellular matrix recombinant protein supramolecular hydrogel is provided for preparing tissue repair products.

[0030] The present invention has the following advantages:

[0031] The invention uses biosynthesized paired cysteine-introduced collagen-like proteins to prepare collagen-like supramolecular hydrogels, which achieve covalent cross-linking between protein molecules without adding any cross-linking agent.

[0032] The present invention is based on the independently developed and designed collagen-like molecules, which have good biocompatibility and cell growth support. Importantly, the collagen-like molecules are prepared by biosynthesis, without involving any chemical synthesis process, and can be prepared without pollution.

[0033] The hydrogel of the present invention can be used as raw material for biomedical products such as tissue repair, cardiovascular stents, nerve damage repair, and drug delivery, and has huge market value potential; the research and development technology is at the world's leading level and can contribute to the subsequent development of biomedical materials. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.

[0035] The structures, proportions, sizes, etc. illustrated in this specification are only used to match the contents disclosed in the specification so as to facilitate understanding and reading by persons familiar with the technology. They are not used to limit the conditions under which the present invention can be implemented, and therefore have no substantial technical significance. Any structural modification, change in proportion or adjustment of size shall still fall within the scope of the technical contents disclosed in the present invention without affecting the effects and purposes that can be achieved by the present invention.

[0036] Figure 1 A flow chart for preparing a biomimetic extracellular matrix recombinant protein supramolecular hydrogel provided in Example 1 of the present invention;

[0037] Figure 2 A collagen-like recombinant protein sequence design provided in Example 1 of the present invention;

[0038] Wherein, A indicates a single paired cysteine ​​sequence; B indicates a multi-paired cysteine ​​sequence;

[0039] Figure 3 A photograph of a spontaneously cross-linked elastin-like hydrogel prepared in Example 1 of the present invention; wherein: A. a photograph of a spontaneously cross-linked elastin-like hydrogel; B. a gel structure simulation; C. a scanning electron microscope photograph of a single-molecule paired cysteine ​​collagen gel; D. a scanning electron microscope photograph of a multi-molecule paired cysteine ​​collagen gel. DETAILED DESCRIPTION

[0040] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the technology can easily understand other advantages and effects of the present invention from the contents described in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0041] Example 1

[0042] This embodiment uses Figure 1 The flowchart shown provides a method for preparing a biomimetic extracellular matrix recombinant protein supramolecular hydrogel:

[0043] Step 1, such as Figure 2 As shown, the basic sequence of collagen-like protein was designed

[0044] The paired cysteine ​​collagen sequence designed by the present invention is MCGGADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDGGPCPPCRYPISRPRKRGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGGPCPPCRGDGGC. The method mainly introduces V-domin at the N-terminus of the scl-2 gene from Streptococcus pyogenes and connects it with the CPPC polypeptide. The triple scl-2 gene is inserted in the middle, and then two polypeptides, CPPC and RGD, are inserted. Importantly, single paired cysteine ​​polypeptides, CGG and GGC, are introduced at the N-terminus and C-terminus of the overall sequence, respectively.

[0045] Step 2: Expression and purification of target protein

[0046] That is, the protein expression plasmid was transformed into BL21 (DE3) Escherichia coli competent cells, the target protein was induced to express, and the protein was purified by nickel column affinity chromatography. Take 1 μL of the correctly constructed recombinant protein expression plasmid and add it to the BL21 (DE3) competent cells, place it on ice for 5 minutes, heat shock it at 42°C for 1.5 minutes, add 200 μL of non-antibiotic liquid LB medium, incubate it at 37°C 180rpm / min for 10 minutes, apply 10 μL on a solid medium plate with kana resistance, and culture it in a 37°C incubator overnight. After about 12 hours, pick a single clone and place it in a kana resistance liquid LB medium, and culture it in a shaker at 180rpm / min and 37°C until the bacterial solution becomes turbid. Take 1mL of bacterial solution and inoculate it in 1L of liquid LB containing 1mL of kana, culture the bacterial solution at 37°C, 200rpm / min, and the OD value is about 0.6-0.8, add 0.3mM IPTG, and culture it at 16°C overnight. The overnight induced expression of the recombinant protein bacterial solution was centrifuged at 5000rpm / min for 10min, and the supernatant was discarded. After the bacterial cells were collected, they were ultrasonicated for 3s using an ultrasonic cell disruptor and stopped for 6s until the cells were completely lysed. Under the conditions of lysis buffer (lysis buffer: 500mM NaCl, 25mM Tris-HCl8.0), centrifuged at 13000rpm / min for 1h, leaving the supernatant suspension, and removing the insoluble cell fragments. The supernatant was added to the balanced nickel column matrix, and after binding, it was eluted with elution buffer to obtain the purified collagen-like protein.

[0047] Step 3: Preparation of hydrogel

[0048] Utilizing the reaction principle of thiol-disulfide exchange reaction activated in a weak acid environment, the paired cysteine ​​collagen dissolved in PBS is added dropwise at a 10% (w / v) content to a pre-prepared weak acid (PH=4-5) acetate buffer and allowed to react for 48 hours. After the reaction, the solution is placed in a prefabricated PDMS mold and left at 4°C for 48 hours. After inducing spontaneous cross-linking of the collagen, the system is placed in a freeze dryer and freeze-dried for 48 hours. After collecting the lyophilized body, the lyophilized powder is re-dissolved with ultrapure water at a concentration of 10% (w / v), and shaken until the lyophilized body is completely dissolved to obtain a hydrogel with a structure such as Figure 3 shown.

[0049] Example 2

[0050] This embodiment provides a method for preparing a biomimetic extracellular matrix recombinant protein supramolecular hydrogel:

[0051] Step 1: Design collagen-like basic sequence

[0052] The paired cysteine ​​collagen sequence designed by the present invention is MCGGCGGADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDGGPCPPCRYPISRPRKRGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGGPCPPCRGDGGCGGC. The main method is to introduce V-domin at the N-terminus of the scl-2 gene from Streptococcus pyogenes and connect it with the CPPC polypeptide. The triple scl-2 gene is inserted in the middle, and then two polypeptides, CPPC and RGD, are inserted. It is important to introduce multiple paired cysteine ​​polypeptides, CGG and GGC, at the N-terminus and C-terminus of the overall sequence, respectively, and the number of cysteine ​​polypeptides at both ends is equal, that is, n N =n C .

[0053] Step 2: Expression and purification of target protein

[0054] That is, the protein expression plasmid was transformed into BL21 (DE3) Escherichia coli competent cells, the target protein was induced to express, and the protein was purified by nickel column affinity chromatography. Take 1 μL of the correctly constructed recombinant protein expression plasmid and add it to the BL21 (DE3) competent cells, place it on ice for 5 minutes, heat shock it at 42°C for 1.5 minutes, add 200 μL of non-antibiotic liquid LB medium, incubate it at 37°C 180rpm / min for 10 minutes, apply 10 μL on a solid medium plate with kana resistance, and culture it in a 37°C incubator overnight. After about 12 hours, pick a single clone and place it in a kana resistance liquid LB medium, and culture it in a shaker at 180rpm / min and 37°C until the bacterial solution becomes turbid. Take 1mL of bacterial solution and inoculate it in 1L of liquid LB containing 1mL of kana, culture the bacterial solution at 37°C, 200rpm / min, and the OD value is about 0.6-0.8, add 0.3mM IPTG, and culture it at 16°C overnight. The overnight induced expression of the recombinant protein bacterial solution was centrifuged at 5000rpm / min for 10min, and the supernatant was discarded. After the bacterial cells were collected, they were ultrasonicated for 3s using an ultrasonic cell disruptor and stopped for 6s until the cells were completely lysed. Under the conditions of lysis buffer (lysis buffer: 500mM NaCl, 25mM Tris-HCl8.0), centrifuged at 13000rpm / min for 1h, leaving the supernatant suspension, and removing insoluble cell fragments. The supernatant was added to the pre-equilibrated nickel column matrix, and after binding, it was eluted with elution buffer to obtain the purified collagen-like protein.

[0055] Step 3: Preparation of hydrogel

[0056] Using the reaction principle of thiol-disulfide exchange reaction activated in a weak acid environment, the paired cysteine ​​collagen dissolved in PBS is added dropwise to the pre-prepared weak acid (PH=4-5) acetate buffer at a content of 10% (w / v) and reacted for 48 hours. After the reaction, the solution is placed in a pre-made PDMS mold and placed at 4°C for 48 hours. After inducing spontaneous cross-linking of the collagen-like protein, the system is placed in a freeze dryer and freeze-dried for 48 hours. After collecting the lyophilized body, the lyophilized powder is re-dissolved with ultrapure water at a concentration of 10% (w / v), and shaken until the lyophilized body is completely dissolved to obtain the hydrogel.

[0057] Example 3

[0058] The number of the CGG at the front end and the GGC at the rear end can be one, such as in Example 1; or two, such as in Example 2; or any number greater than 2. This embodiment provides a method for preparing a universal biomimetic extracellular matrix recombinant protein supramolecular hydrogel:

[0059] Step 1: Design collagen-like basic sequence

[0060] The paired cysteine ​​collagen sequence designed by the present invention is M(CGG)n N ADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDGGPCPPCRYPISRPRKRGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAG PKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGGPCPPCRGD(GGC)n C .

[0061] The main method is to introduce V-domin at the N-terminus of the scl-2 gene from Streptococcus pyogenes and connect it with the CPPC polypeptide. The triple scl-2 gene is inserted in the middle, and then two polypeptides, CPPC and RGD, are inserted. It is important to introduce multiple paired cysteine ​​polypeptides, CGG and GGC, at the N-terminus and C-terminus of the overall sequence, respectively, and the number of cysteine ​​polypeptides at both ends is equal, that is, n N =n C (n is any positive integer).

[0062] Step 2: Expression and purification of target protein

[0063] That is, the protein expression plasmid was transformed into BL21 (DE3) Escherichia coli competent cells, the target protein was induced to express, and the protein was purified by nickel column affinity chromatography. Take 1 μL of the correctly constructed recombinant protein expression plasmid and add it to the BL21 (DE3) competent cells, place it on ice for 5 minutes, heat shock it at 42°C for 1.5 minutes, add 200 μL of non-antibiotic liquid LB medium, incubate it at 37°C 180rpm / min for 10 minutes, apply 10 μL on a solid medium plate with kana resistance, and culture it in a 37°C incubator overnight. After about 12 hours, pick a single clone and place it in a kana resistance liquid LB medium, and culture it in a shaker at 180rpm / min and 37°C until the bacterial solution becomes turbid. Take 1mL of bacterial solution and inoculate it in 1L of liquid LB containing 1mL of kana, culture the bacterial solution at 37°C, 200rpm / min, and the OD value is about 0.6-0.8, add 0.3mM IPTG, and culture it at 16°C overnight. The overnight induced expression of the recombinant protein bacterial solution was centrifuged at 5000rpm / min for 10min, and the supernatant was discarded. After the bacterial cells were collected, they were ultrasonicated for 3s using an ultrasonic cell disruptor and stopped for 6s until the cells were completely lysed. Under the conditions of lysis buffer (lysis buffer: 500mM NaCl, 25mM Tris-HCl8.0), centrifuged at 13000rpm / min for 1h, leaving the supernatant suspension, and removing insoluble cell fragments. The supernatant was added to the pre-equilibrated nickel column matrix, and after binding, it was eluted with elution buffer to obtain the purified collagen-like protein.

[0064] Step 3: Preparation of hydrogel

[0065] Using the reaction principle of thiol-disulfide exchange reaction activated in a weak acid environment, the paired cysteine ​​collagen dissolved in PBS was added dropwise to the pre-prepared weak acid (PH=4-5) acetate buffer at a content of 10% (w / v) and reacted for 48 hours. After the reaction, the solution was placed in a pre-made PDMS mold and placed at 4°C for 48 hours. After inducing spontaneous cross-linking of the collagen-like protein, the system was placed in a freeze dryer and freeze-dried for 48 hours. After collecting the lyophilized body, the lyophilized powder was re-dissolved with ultrapure water at a concentration of 10% (w / v), and shaken until the lyophilized body was completely dissolved to obtain a hydrogel.

[0066] Comparative Example 1

[0067] This comparative example provides a method for preparing an existing hydrogel:

[0068] Sodium alginate (SA) was added into NaCl solution, and the solution was stirred evenly at room temperature to obtain a 3% SA solution. A mixed solution of 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) was added, and the solution was activated at 4°C for 3 hours. A 3% carboxymethyl chitosan (CMCS) aqueous solution was prepared, and the two liquids were mixed to prepare a hydrogel. The prepared SA / CMCS hydrogel was loaded with 1% effective extract of Acanthopanax senticosus / Cassia bark Osmanthus fragrans to obtain Acanthopanax senticosus / Cassia bark Osmanthus fragrans loaded SA / CMCS hydrogel.

[0069] The results show that the Acanthopanax senticosus / Cassia bark and Osmanthus fragrans SA / CMCS hydrogel dressing has good mechanical strength, physicochemical properties and antibacterial and anti-inflammatory functions, and has the potential to be developed into a new type of wound dressing. Compared with the present invention, the method for making hydrogels contains chemical drug extracts in the added materials, and there are more types of additives, the operation steps are more complicated, and the side effects are greater; however, the hydrogel of the present invention does not need to add additional drug extracts, that is, a hydrogel with strong mechanical strength, excellent physicochemical properties and good antibacterial and anti-inflammatory properties can be obtained.

[0070] Comparative Example 2

[0071] This comparative example provides a method for preparing an existing hydrogel:

[0072] First, add different amounts of starch and low molecular weight polyester (relative molecular weight of about 300g / mol) to the (polyvinyl alcohol) PVA raw material according to the plasticizing formula, then add distilled water equal to the PVA to mix, stir thoroughly, and place at room temperature for 12 hours to fully swell. The swollen PVA mixture is added to an internal mixer for melt blending. The internal mixer processing temperature is set to 95°C for 10 minutes to obtain a PVA plasticized modified material. Take 5g of the blended and modified PVA plasticized modified material, use a flat vulcanizer to press it into a film of a specified thickness, seal it for storage, set the upper and lower plates of the flat vulcanizer to 95°C, and the pressure is 20MPa to make a PVA hydrogel film. Among them, the gel content of the PVA hydrogel film increases with the increase of the relative molecular weight of PVA. However, the process of preparing the hydrogel is relatively complicated, and other chemical materials are added, which reduces its biocompatibility; but the present invention is prepared by a purely biological method, so it has better biocompatibility.

[0073] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

[0074]

[0075]

[0076]

[0077]

Claims

1. A method for preparing a genetically encoded recombinant collagen-like supramolecular hydrogel, characterized in that: The method comprises: The paired cysteine ​​collagen dissolved in PBS was added dropwise to the pre-prepared weakly acidic acetate buffer at a content of 10% w / v, and reacted for 48 hours. After the reaction, the solution was placed in a pre-made PDMS mold and placed at 4°C for 48 hours. After inducing spontaneous cross-linking of the collagen, the system was placed in a freeze dryer and freeze-dried for 48 hours. After the freeze-dried body was collected, the freeze-dried powder was re-dissolved with ultrapure water at a concentration of 10% w / v, and shaken until the freeze-dried body was completely dissolved, thereby obtaining a hydrogel. Wherein, the amino acid sequence of the paired cysteine ​​collagen is: M(CGG)nNADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDGGPCPPCRYPISRPRKRGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKG EQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGPKGEQGPQGLPGKDGEAGAQGPAGPMGPAGEQGEKGEPGTQGAKEDRGETGPKGPKGERGEAGPAGKDGEPGPVGPAGGPCPPCRGD(GGC)nC, nN=nC, and is 1 or 2; The pH of the weakly acidic acetate buffer is 4-5.